Jobs
View more job listings or post a job
Genentech Scientist/ Senior Scientist, Small Molecule Pharmaceutics 
Genentech Senior Scientific Researcher_Bioanalysis
Jazz Pharmaceuticals Associate Director, Early Development Pharmacologist
UC Davis - Equine Analytical Chemistry Program LC/MS CHEMIST - STAFF RESEARCH ASSOCIATE 3        
Genentech Associate Scientist/Scientist - Biotransformation, Drug Metabolism And Pharmacokinetics (DMPK)
UC Davis - Equine Analytical Chemistry Program LC/MS CONFIRMATION SUPERVISOR (LABORATORY RESEARCH SUPERVISOR 2)  
Jazz Pharmaceuticals Head of Toxicology
Dow Development Laboratories Formulation Chemist
Genentech Scientist, DMPK
Post a job

Symposium

Covalent Inhibitor Drug Discovery & Development: Biology, Chemistry, PK, Safety and Case Studies (Jointly with Bay Area PKPD Network)


Speakers: Tom Baillie (Univ Washington), Jack Taunton (UCSF), Joachim Rudolph (Genentech), Dane Karr (Nurix), Zhengping Wang (Revolution Medicine), Shirin Kapur (ex-Onyx), Leah Schutt- (Genentech), Betty Chang (ex-Pharmacyclics)
Organizers: Xu (Richard) Zang, PhD (Genentech)
Date: 2019-02-07
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location: Crowne Plaza, Foster City, CA
Major Sponsor: (1)Correlia Biosystems;(Major Sponsorship - Afternoon still open)
Vendor show vendors registered to date: (20)AIT Bioscience; Alturas Analytics; Averica Discovery Services; BioDuro; BioreclamationIVT; cgenetool; CMIC Inc.; Cytovier LLC; Intertek; MagArray; MedChemExpress; Medpace; MicroConstants; MRIGlobal; Nucleo Life Sciences; Q2 Solutions; Sekisui XenoTech, LLC; Selvita Inc.; Seventh Wave; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2019-02-04  (it will close sooner if the seating cap is reached)

About the Topic

In recent years, there has been a renewed interest in drug development of covalent inhibitors.  Several of these inhibitors have been approved by the FDA and EMA and more covalent inhibitors are in early and late stage development.  Covalent inhibitors can have superior affinity towards target proteins compared to their non-covalent counterparts, potentially resulting in improved therapeutic benefit.  This symposium will cover a wide range topics pertaining to covalent inhibitors discovery and development

Key Topics:

  • Targeted Covalent Inhibitors for Drug Design – Tom Baillie (UW)
  • Kinetic selectivity with lysine-targeted kinase inhibitors – Jack Taunton (UCSF)
  • Covalent modification in drug discovery - a chemist's perspective – Joachim Rudolph (Genentech)
  • Preclinical challenges for reversible covalent inhibitors – Dane Karr (Principia)
  • Development of covalent proteosome inhibitors: DMPK and clinical pharmacology perspectives – Zhengping Wang (Revolution Medicine)
  • Benchmark for Selective Sustained Proteasome Inhibition – Shirin Kapur (Cortexyme)
  • Safety Considerations for Covalent Inhibitors - Leah Schutt- (Genentech)
  • From bench to bedside: The story of a first-in-class covalent BTK inhibitor ibrutinib– Betty Chang


Agenda:

8:45-8:55           Welcome and overview - Richard Zang / Shichang Miao

8:55-9:40           Targeted Covalent Inhibitors for Drug Design - Tom Baillie

9:40-10:25         Kinetic selectivity with lysine-targeted kinase inhibitors - Jack Taunton

10:25-10:35       Major Sponsor's Presentation

10:35-10:50       Break

10:50-11:35       Covalent modification in drug discovery - a chemist's perspective - Joachim Rudolph

11:35-12:20       Safety Considerations for Covalent Inhibitors - Leah Schutt

12:20-13:20       Lunch

13:20-14:05       Preclinical challenges for reversible covalent inhibitors - Dane Karr

14:05-14:50       From bench to beside:  The story of a first-in-class covalent BTK inhibitor ibrutinib - Betty Chang

14:50-15:00       Major Sponsor's Presentation

15:00-15:15       Break

15:15-16:00       Benchmark for Selective Sustained Proteasome Inhibition - Shirin Kapur

16:00-16:45       Development of covalent proteasome inhibitors: DMPK and clinical pharmacology perspectives - Zhengping Wang

16:45-17:15       Panel Discussion


2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-10-18, Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In Vitro Diagnostics, Companion Diagnostics and Precision Medicine
2020-01-21, Best Practices for Clinical Trial Design
2020-02-11, Drug-Device Combination
2020-02-24, Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 8/20/2019; Visited: 1226; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

UC Davis UC Davis LC/MS Confirmation Supervisor (Lab Rsch Supv 2) Apply Online: http://50.73.55.13/counter.php?id=165482 UC Davis is an AA/EOE
XCELERATE at Biotech Week Boston Driving the Future of the Life Science Industry. Sept. 11 at BCEC. Learn more.
BIOTECH WEEK BOSTON - Sept. 9-12 Access over 5,000 of the most innovative scientific minds & business leaders in Boston and around the world. Learn More.
Submit a Text Ad